CNS Drug Delivery in Stroke: Improving Therapeutic Translation From the Bench to the Bedside.

ABSTRACT: Drug development for ischemic stroke is challenging as evidenced by the paucity of therapeutics that have advanced beyond a phase III trial. There are many reasons for this lack of clinical translation including factors related to the experimental design of preclinical studies. Often overlooked in therapeutic development for ischemic stroke is the requirement of effective drug delivery to the brain, which is critical for neuroprotective efficacy of several small and large molecule drugs. Advancing central nervous system drug delivery technologies implies a need for detailed comprehension of the blood-brain barrier (BBB) and neurovascular unit. Such knowledge will permit the innate biology of the BBB/neurovascular unit to be leveraged for improved bench-to-bedside translation of novel strok

SUBMITTER: Ronaldson PT 

PROVIDER: S-EPMC10752297 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature